Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The clinical effectiveness of opioid maintenance for heroin dependence is believed to result from a medication's ability to decrease mu-opioid receptor (muOR) availability thereby replacing agonist effects, alleviating withdrawal symptoms and attenuating heroin effects. We empirically tested this hypothesis in five heroin-dependent volunteers who were successively maintained on 32, 16, 2, and 0 mg daily buprenorphine (BUP) tablet doses. We predicted and confirmed that higher BUP doses would decrease in vivo muOR availability (measured with PET and [(11)C]carfentanil), increase plasma levels of BUP and its metabolite nor-BUP, and decrease withdrawal symptoms and hydromorphone (HYD) responses. Relative to placebo, BUP significantly decreased mean (+/-SEM) whole-brain muOR availability 41+/-8, 80+/-2, and 84+/-2% at 2, 16, and 32 mg, respectively. Regions of interest (ROIs) (prefrontal cortex, anterior cingulate, thalamus, amygdala, nucleus accumbens, caudate) showed similar dose-dependent effects. Changes in muOR availability varied across ROIs (prefrontal cortex, 47% vs amygdala, 27%) at BUP 2 mg, but were more homogeneous across ROIs at BUP 32 mg (94-98%; except thalamus, 88%). Relative to placebo (0 ng/ml), peak plasma levels of BUP and nor-BUP were comparable and dose-dependent (0.5-1, 5-6, and 13-14 ng/ml at 2, 16, and 32 mg, respectively). muOR availability decreases were negatively correlated with BUP plasma level and positively correlated with questionnaire-based opioid withdrawal symptoms and attenuation of HYD symptoms. These findings suggest that high-dose BUP maintenance produces near-maximal muOR occupation, muOR availability correlates well with plasma levels, and BUP-related opioid symptoms and antagonist blockade exhibit concentration-effect relationships.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There was a single study by Greenwald et al. 17 (as reported in Greenwald et al. 18 ) that reported occupancy data for mu-opioid occupancy for buprenorphine.”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“We derived a curve of best fit for buprenorphine from dose-occupancy data in Greenwald et al. 17 (as reported in Greenwald et al. 18 ) where occupancy was measured 4 h after 12 days of maintenance treatment with doses ranging from 1 to 32 mg (Figure 2 and Table 3).”
From Tapering and withdrawing opioids: guidance informed by fundamental principles to minimise withdrawal symptoms (2025) · cites this paper as [17]
In the citing paper
“This was corroborated by Greenwald et al. (117) who found that higher buprenorphine doses (up to 32 mg given as a tablet*) led to increased plasma buprenorphine levels, decreased μ-opioid receptor availability, and decreased withdrawal symptoms.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
In the citing paper
“In the same study, heroin craving was found to be significantly correlated with μ-opioid receptor availability and negatively correlated with buprenorphine plasma levels.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [117]
Citations
Cites
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688 · cited 1×
“The global binding potential value was calculated using SPM99 (Friston et al, 1995) as the average value across all brain voxels.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“An experienced clinician administered a semistructured interview (SCID-IV; First et al, 1996), and opioid dependence severity was determined using the Addiction Severity Index (McLellan et al, 1985a, b).”
MethodMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationJasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782 · cited 1×
“Earlier human laboratory studies showed that administration of subcutaneous BUP (Jasinski et al, 1978; Mello et al, 1982) or sublingual BUP liquid (Bickel et al, 1988; Rosen et al, 1994; Walsh et al, 1995) could attenuate the reinforcing, subjective, and physiological effects of mOR agonists.”
BackgroundA Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethodAGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT
COWAN, A., LEWIS, J. W., & MACFARLANE, I. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb07532.x · Cited by 528
Meyer, C. R., Boes, J. L., Kim, B., Bland, P. H., Zasadny, K. R., Kison, P. V., Koral, K., Frey, K. A., & Wahl, R. L. (1997) · Medical Image Analysis · doi:10.1016/s1361-8415(97)85010-4 · Cited by 460
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402 · cited 2×
“Numerous clinical trials support the safety and efficacy of BUP (eg Fudala et al, 1990; Johnson et al, 1995, 2000; Ling et al, 1998), which led to US Food and Drug Administration approval in October 2002 of two sublingual tablet formulations (BUP alone (Subutext) or combined with naloxone using a 4…”
BackgroundMethod
Research works printed but not linked: 2
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, NY State Psychiatric Institute: New York.
- Lewis JW, Rance MJ, Sanger DJ (1983). The pharmacology and abuse potential of buprenorphine: a new antagonist analgesic. In: Mello NK (ed). Advances in Substance Abuse Vol. 3 JAI Press: Greenwich, 103–154.
Cited by
Items 101–200 of 348
Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies
Li, X., Shorter, D. I., & Kosten, T. R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.955469 · Cited by 39
Human brain imaging and substance abuse
Lingford-Hughes, A. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.10.002 · Cited by 38
Sorge, R. E., & Stewart, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0485-1 · Cited by 36
Reid, A. G., Lingford-Hughes, A. R., Cancela, L. M., & Kalivas, P. W. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00024-3 · Cited by 36
Top Ten Tips Palliative Care Clinicians Should Know About Buprenorphine
Neale, K., Weimer, M. B., Davis, M. P., Jones, K. F., Kullgren, J. G., Kale, S. S., Childers, J. W., Broglio, K., Merlin, J. S., Peck, S., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0399 · Cited by 34
Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
Laffont, C. M., Ngaimisi, E., Gopalakrishnan, M., Ivaturi, V. D., Young, M. A., Greenwald, M. K., & Heidbreder, C. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1052113 · Cited by 34
Self-citationBuprenorphine in Neonatal Abstinence Syndrome
Kraft, W. K. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.930 · Cited by 34
Azar, P., Wong, J. S. H., Jassemi, S., Moore, E. M., Vo, D. X., Nikoo, M., & Young, S. (2020) · American Journal on Addictions · doi:10.1111/ajad.13050 · Cited by 34
Ruggiero, A., Coccia, P., Arena, R., Maurizi, P., Battista, A., Ridola, V., Attinà, G., & Riccardi, R. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24332 · Cited by 33
Brünen, S., Vincent, P. D., Baumann, P., Hiemke, C., & Havemann‐Reinecke, U. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31822fbf7c · Cited by 32
Kalluri, H. V., Zhang, H., Caritis, S. N., & Venkataramanan, R. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13368 · Cited by 32
Dhawan, J., Deng, H., Gatley, S. J., Makriyannis, A., Akinfeleye, T., Bruneus, M., Dimaio, A. A., & Gifford, A. N. (2006) · Synapse · doi:10.1002/syn.20277 · Cited by 32
Management of women treated with buprenorphine during pregnancy
Alto, W. A., & O’Connor, A. B. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.04.001 · Cited by 31
[ 11 C]Carfentanil Binds Preferentially to μ-Opioid Receptor Subtype 1 Compared to Subtype 2
Eriksson, O., & Antoni, G. (2015) · Molecular Imaging · doi:10.2310/7290.2015.00019 · Cited by 31
Blecha, J. E., Henderson, B. D., Hockley, B. G., VanBrocklin, H. F., Zubieta, J., DaSilva, A. F. M., Kilbourn, M. R., Koeppe, R. A., Scott, P. J. H., & Shao, X. (2017) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3513 · Cited by 31
Self-citationHickey, T. R., Costa, G. P. A., de Oliveira, D. S., Podosek, A., Abelleira, A., Avila-Quintero, V. J., & Aquino, J. P. D. (2025) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2024-106014 · Cited by 29
Transdermal Buprenorphine for Acute Pain in the Clinical Setting: A Narrative Review
Pergolizzi, J. V., Magnusson, P., LeQuang, J. A., Breve, F., Mitchell, K., Chopra, M., & Varrassi, G. (2021) · Journal of Pain Research · doi:10.2147/jpr.s280572 · Cited by 29
Efficacy of continuing medical education to reduce the risk of buprenorphine diversion
Lofwall, M. R., Wunsch, M. J., Nuzzo, P. A., & WALSH, S. L. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.04.008 · Cited by 29
Buprenorphine and pain treatment in pediatric patients: an update
Vicencio-Rosas, E., Pérez-Guillé, M.-G., Pérez, C. F., Flores‐Pérez, J., Jiménez, F. T., & Chávez-Pacheco, J. L. (2018) · Journal of Pain Research · doi:10.2147/jpr.s153903 · Cited by 29
Shafer, S. L., & Flood, P. D. (2008) · Springer eBooks · doi:10.1007/978-0-387-72527-7_15 · Cited by 30
Novel Long-Acting Buprenorphine Medications for Opioid Dependence: Current Update
Soyka, M. (2020) · Pharmacopsychiatry · doi:10.1055/a-1298-4508 · Cited by 28
Buprenorphine Microdosing for the Pain and Palliative Care Clinician
Quirk, K. C., & Stevenson, M. H. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2021.0378 · Cited by 27
Treatment of opioid dependence with buprenorphine: current update
Soyka, M. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.3/msoyka · Cited by 26
Medications Development for Treatment of Opioid Use Disorder
Townsend, E. A., Negus, S. S., & Banks, M. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039263 · Cited by 26
Serpell, M. G., Tripathi, S. S., Scherzinger, S., Rojas‐Farreras, S., Oksche, A., & Wilson, M. (2015) · Patient · doi:10.1007/s40271-015-0151-y · Cited by 24
Acampora, G. A., Nisavic, M., & Zhang, Y. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19com12810 · Cited by 23
Seah, S., Asad, A. B. A., Baumgartner, R., Dai, F., Williams, D. S., Manigbas, E., Beaver, J. D., Reese, T., Henry, B., Evelhoch, J. L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110432 · Cited by 23
Khemiri, A., Kharitonova, E., Zah, V., Ruby, J., & Toumi, M. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2805 · Cited by 23
Buprenorphine treatment for opioid use disorder: recent progress
Parida, S., Carroll, K. M., Petrakis, I. L., & Sofuoglu, M. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1635454 · Cited by 23
Perioperative Buprenorphine Management
Hickey, T. R., Abelleira, A., Acampora, G. A., Becker, W. C., Falker, C. G., Nazario, M., & Weimer, M. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.09.001 · Cited by 23
On subclasses of opioid analgesics
Raffa, R. B. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.952717 · Cited by 23
Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder
Maremmani, I., Demattéis, M., Gorzelańczyk, E. J., Mugelli, A., Walcher, S., & Torrens, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175575 · Cited by 22
Hammers, A., & Lingford-Hughes, A. R. (2006) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2006.06.004 · Cited by 22
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits
Davis, M. P. (2025) · Drugs · doi:10.1007/s40265-024-02128-y · Cited by 21
Soyka, M., & Franke, A. G. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i9.543 · Cited by 21
Rudolph, K. E., Williams, N., Goodwin, A. T. S., Shulman, M., Fishman, M. J., Diaz, I. M., Luo, S. X., Rotrosen, J., & Nunes, E. V. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109609 · Cited by 21
Moody, D. E. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.783567 · Cited by 21
Self-citationBeing Fed Up: A Social Cognitive Neuroscience Approach to Mental Satiation
Mojzisch, A., & Schulz‐Hardt, S. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1412.006 · Cited by 21
Suboxone Misuse Along the Opiate Maintenance Treatment Pathway
Furst, R. T. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759860 · Cited by 21
Romero-González, M., Shahanaghi, A., DiGirolamo, G. J., & Gonzalez, G. M. (2017) · American Journal on Addictions · doi:10.1111/ajad.12641 · Cited by 21
Greenwald, M. K. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.1.52 · Cited by 22
Self-citationUpadhyay, J., Verrico, C. D., Cay, M., Kodele, S., Yammine, L., Koob, G. F., & Schreiber, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00008-0 · Cited by 20
Garland, E. L. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16147 · Cited by 20
Lim, G., Carvalho, B., George, R. B., Bateman, B. T., Brummett, C. M., Ip, V. H. Y., Landau, R., Osmundson, S. S., Raymond, B. L., Richebé, P., et al. (2024) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000007237 · Cited by 23
Cingulate biochemistry in heroin users on substitution pharmacotherapy
Verdejo‐García, A., Lubman, D. I., Roffel, K., Vilar‐López, R., Bora, E., MacKenzie, T., & Yücel, M. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412463088 · Cited by 20
Ballester, J., Baker, A. K., Martikainen, I. K., Koppelmans, V., Zubieta, J.-K., & Love, T. (2022) · Translational Psychiatry · doi:10.1038/s41398-021-01775-z · Cited by 19
Self-citationOffice-Based Opioid Dependence Treatment
Colson, J. D., Helm, S., & Silverman, S. M. (2012) · Pain Physician · doi:10.36076/ppj.2012/15/es231 · Cited by 19
Hamata, B., Griesdale, D. E. G., Hann, J., & Azar, P. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000675 · Cited by 19
Reversibility of opioid receptor occupancy of buprenorphine in vivo
Englberger, W., Kögel, B. Y., Friderichs, E., Straβburger, W., & Germann, T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.022 · Cited by 18
Auvity, S., Goutal, S., Caillé, F., Vodovar, D., Pruvost, A., Wimberley, C., Leroy, C., Tonietto, M., Bottlaender, M., & Tournier, N. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-00976-w · Cited by 17
Buprenorphine dosing choices in specific populations: review of expert opinion
Maremmani, I., Rolland, B., Somaini, L., Roncero, C., Reimer, J., Wright, N. M. J., Littlewood, R., Krajči, P., Alho, H., D’Agnone, O., et al. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1209486 · Cited by 17
Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain
Haber, L. A., DeFries, T., & Martín, M. (2019) · Journal of Hospital Medicine · doi:10.12788/jhm.3265 · Cited by 17
Acute Pain Management in People With Opioid Use Disorder: A Systematic Review
Buonora, M. J., Mackey, K., Khalid, L., Hickey, T. R., Grimshaw, A. A., Moss, M., Starrels, J. L., Alford, D. P., Becker, W. C., & Weimer, M. B. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-01917 · Cited by 16
Licina, L., Hamsher, C. P., Lautenschager, K., Dhanjal, S. T., Williams, N., & Spevak, C. (2013) · Military Medicine · doi:10.7205/milmed-d-12-00310 · Cited by 16
Ismail, S., & Haron, M. (2015) · Pharmacognosy Research · doi:10.4103/0974-8490.159580 · Cited by 16
Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence
Soyka, M. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.729574 · Cited by 15
Smith, K. E., Tillson, M. D., Staton, M., & Winston, E. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107837 · Cited by 15
Azar, P., Mathew, N., Mahal, D., Wong, J. S. H., Westenberg, J. N., Schütz, C. G., & Greenwald, M. K. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2039814 · Cited by 15
Self-citationPET and SPECT in Drug and Substance Abuse
Mena, J. C., Cuellar, H., Vargas, D., & Riascos, R. (2005) · Topics in Magnetic Resonance Imaging · doi:10.1097/01.rmr.0000192177.01789.c0 · Cited by 15
The patient with substance use disorder
Anițescu, M. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000738 · Cited by 14
Ritvo, A. D., Calcaterra, S. L., & Ritvo, J. I. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000738 · Cited by 14
Guerra, S. G., Spadoni, A. D., Mitchell, J., & Strigo, I. A. (2022) · Brain Research · doi:10.1016/j.brainres.2023.148268 · Cited by 14
18F-Labeled sufentanil for PET-imaging of μ-opioid receptors
Henriksen, G., Platzer, S., Hauser, A., Willoch, F., Berthele, A., Schwaiger, M., & Wester, H. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.049 · Cited by 14
Handbook of Methadone Prescribing and Buprenorphine Therapy
Cruciani, R. A., & Knotková, H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2 · Cited by 14
Perioperative Management of Extended-release Buprenorphine
Hickey, T. R., Henry, J. T., Edens, E. L., Gordon, A. J., & Acampora, G. A. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001024 · Cited by 13
A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder
Miller, J. C., Brooks, M. A., Wurzel, K. E., Cox, E. J., & Wurzel, J. F. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00443-5 · Cited by 13
Small Molecule Receptors as Imaging Targets
Hagooly, A., Rossin, R., & Welch, M. J. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-77496-9_5 · Cited by 13
Greenwald, M. K., Woodcock, E. A., Khatib, D., & Stanley, J. A. (2015) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2015.07.002 · Cited by 13
Self-citationFrontline Perspectives on Buprenorphine for the Management of Chronic Pain
Adler, J. A., Mallick‐Searle, T., Garofoli, M., & Zimmerman, A. (2024) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s449748 · Cited by 12
Mount, J., Sun, J., Davis, A., Cover, A. A., Sun, L., Gannon, C., Derenoncourt, M., Garrett, G., Eyasu, R., Ebah, E., et al. (2024) · Addiction · doi:10.1111/add.16600 · Cited by 12
Gold, J. I., Townsend, J., Jury, D. L., Kant, A. J., Gallardo, C. C., & Joseph, M. H. (2006) · Seminars in Anesthesia Perioperative Medicine and Pain · doi:10.1053/j.sane.2006.05.014 · Cited by 12
Silverman, S. M., Raffa, R. B., Cataldo, M., Kwarcinski, M., & Ripa, S. R. (2017) · Journal of Pain Research · doi:10.2147/jpr.s132595 · Cited by 12
Lim, G., Carvalho, B., George, R. B., Bateman, B. T., Brummett, C. M., Ip, V. H. Y., Landau, R., Osmundson, S. S., Raymond, B. L., Richebé, P., et al. (2025) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.12.006 · Cited by 12
Martucci, K. T. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.04.005 · Cited by 11
Selitsky, L., Nordeck, C. D., Truong, A. Q., Agus, D., & Buresh, M. (2022) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.208981 · Cited by 11
Furo, H., Wiegand, T. J., Rani, M., Schwartz, D. G., Sullivan, R. W., & Elkin, P. L. (2023) · Substance Abuse Research and Treatment · doi:10.1177/11782218231153748 · Cited by 11
Antagonist Treatment of Opioid Withdrawal: Translational Low Dose Approach
Mannelli, P., Gottheil, E., & Bockstaele, E. J. V. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n02_01 · Cited by 11
Cumming, P. D., Caprioli, D., & Dalley, J. W. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01036.x · Cited by 11
Approved medications for opioid use disorder : current update
Soyka, M. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2507124 · Cited by 10
Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine
Bormann, N. L., Gout, A., Kijewski, V., & Lynch, A. (2022) · F1000Research · doi:10.12688/f1000research.120821.2 · Cited by 10
Balancing acts: The dual faces of fentanyl in medicine and public health
Khatoon, H., & Faudzi, S. M. M. (2024) · Legal Medicine · doi:10.1016/j.legalmed.2024.102507 · Cited by 10
Acute Pain Management in Traumatically Injured Patients With Outpatient Buprenorphine Therapy
Culshaw, J., Philpott, C. D., Bradshaw, P. G., Brizzi, M. B., Goodman, M. D., Makley, A. T., Reinstatler, K. M., & Droege, M. E. (2023) · Journal of Surgical Research · doi:10.1016/j.jss.2023.03.021 · Cited by 10
Rudolph, K. E., Shulman, M., Fishman, M. J., Diaz, I. M., Rotrosen, J., & Nunes, E. V. (2021) · Addiction · doi:10.1111/add.15654 · Cited by 10
Henriksen, G., Willoch, F., Talbot, P. S., & Wester, H. (2006) · Drug Development Research · doi:10.1002/ddr.20161 · Cited by 11
Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution
Soyka, M., & Pogarell, O. M. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0783-6 · Cited by 10
Hitt, J. M., Elkin, P. L., & de León-Casasola, O. A. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005291 · Cited by 9
Ende, H. B., Bauchat, J. R., Sorabella, L. L., Raymond, B. L., Feng, X., Shotwell, M. S., & Richardson, M. G. (2021) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2021.110600 · Cited by 9
Schuster, B., Bell, B., Massoll, A., & White, S. (2022) · Cureus · doi:10.7759/cureus.23385 · Cited by 9
Perioperative Management of Extended-Release Buprenorphine: A Narrative Review and Case Series
Hickey, T. R., Meeks, T. W., Oxentine, H., Park, D. C., Abelleira, A., Edens, E. L., Gordon, A. J., & Acampora, G. A. (2023) · Substance Abuse · doi:10.1177/08897077231167043 · Cited by 9
An anesthesiologist‐led inpatient buprenorphine initiative
Patel, N., Schwenk, E. S., Ferd, P., Torjman, M. C., Baratta, J. L., & Viscusi, E. R. (2021) · Pain Practice · doi:10.1111/papr.12996 · Cited by 9
Phillips, S. J., Oliveto, A. H., Mancino, M. J., & Hendrickson, H. P. (2021) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9104 · Cited by 9
Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome
Eudy‐Byrne, R. J., Zane, N. R., Adeniyi-Jones, S. C., Gastonguay, M. R., Ruiz-García, A., Kaushal, G., & Kraft, W. K. (2021) · Clinical and Translational Science · doi:10.1111/cts.13074 · Cited by 9
Bergen, A. W., Baurley, J. W., Ervin, C. M., McMahan, C. S., Bible, J., Stafford, R. S., Mudumbai, S. C., & Saxon, A. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074106 · Cited by 9
Wadsak, W., Mien, L., Ettlinger, D. E., Feitscher, S., Lanzenberger, R. R., Marton, J., Dudczak, R., Kletter, K., & Mitterhauser, M. (2007) · Radiochimica Acta · doi:10.1524/ract.2007.95.1.33 · Cited by 8
Marinangeli, F., Guetti, C., Angeletti, C., Bonetti, C., Paladini, A., Piroli, A., & Varrassi, G. (2009) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.05.008 · Cited by 8
Conversion of Schedule II Opioids to Buprenorphine Buccal Film: A Retrospective Analysis
Zimmerman, A., Bikdash, R., & Rauck, R. L. (2020) · Pain Medicine · doi:10.1093/pm/pnaa226 · Cited by 7
Methadone enhances human influenza A virus replication
Chen, Y., Wu, K., Tsai, M., Chien, W., Chen, M., & Wang, Y. (2015) · Addiction Biology · doi:10.1111/adb.12305 · Cited by 7
Vogel, M., Köck, P., Strasser, J., Wiesbeck, G. A., Walter, M., & Dürsteler, K. M. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1610200 · Cited by 7
Comparing Three Formulations of Buprenorphine in an Incisional Pain Model in Mice
Lopez-Echeverria, G., Alamaw, E. D., Gorman, G. S., Jampachaisri, K., Huss, M. K., & Pacharinsak, C. (2023) · Journal of the American Association for Laboratory Animal Science · doi:10.30802/aalas-jaalas-23-000011 · Cited by 6
Shulman, M., Meyers-Ohki, S. E., Novo, P., Provost, S. E., Ohrtman, K., Veldhuisen, P. C. V., Oden, N. L., Otterstatter, M. C., Bailey, G. L., Liu, D., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107816 · Cited by 6
Metadata
- Authors
- Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K.
- Affiliations
- Wayne State University (US)
- University of Utah (US)
- University of Michigan (US)
- Corresponding author
- Greenwald, Mark K
- Venue
- Neuropsychopharmacology
- Published
- 2003-05-30
- Volume
- 28
- Issue
- 11
- Pages
- 2000-2009
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2040327352
- Cited by
- 320
- References
- 44
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 16 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 20 · 2019: 20 · 2018: 11 · 2017: 14 · 2016: 3 · 2015: 12 · 2014: 11 · 2013: 22 · 2012: 14
- FWCI
- 10.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wayne State University
- U.S. Public Health Service (DA00254)
- National Institute on Drug Abuse (R01 DA 10100, P50DA000254, DA-00254, R01DA010100, P50 DA00254, P01DA000254)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- buprenorphine, heroin addiction, opioid maintenance treatment, dose-response relationship, opioid withdrawal symptoms
- MeSH terms
- Adult, Analysis of Variance, Buprenorphine, Dose-Response Relationship, Drug, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotic Antagonists, Tomography, Emission-Computed, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.